Deals this week: Sichuan Kelun Pharma, Ascendis Health, Zhuhai United Labs

Chinese pharmaceutical company Sichuan Kelun Pharmaceutical intends to raise ¥800m ($115.93m) in gross proceeds through a public offering of bonds.

Due 13 March 2022, the bonds will help the company to raise funds required to repay its corporate debts.

Ascendis Health, a South African manufacturer and distributor of healthcare products, has reached an agreement with Sunwave Pharma to acquire the latter’s core business assets.

Based in Romania, Sunwave Pharma distributes nutritional health products.

The purchase consideration for the assets is €16.35m ($17.33m).

Chinese pharmaceutical company Zhuhai United Laboratories intends to raise ¥1.1bn ($159.51m) in gross proceeds through a public offering of corporate bonds.

"Chinese pharmaceutical company Zhuhai United Laboratories intends to raise ¥1.1bn ($159.51m) in gross proceeds through public offering of corporate bonds."

The proceeds are intended to be used to repay bank loans.

US-based biopharmaceutical company Biohaven Pharmaceutical Holding Company has raised $20m from the second tranche of private placement of shares of its common stock following its first tranche in November 2016 that raised $80m.

Venrock and other biotechnology investors subscribed to the offering.

French pharmaceutical company MedDay has acquired Profilomic’s health division, with the aim of strengthening its existing metabolomics research platform, SPECMET.

MedDay provides therapies for neuro-metabolic diseases, whereas Profilomic offers services in chemical, lipidomic and metabolomic analyses.

The acquisition is also expected to help MedDay expand its pipeline of neurological disorder therapies.